|
Jan 30
|
UPDATE 1-2seventy bio to sell experimental cell therapies to Regeneron
|
|
Jan 30
|
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
|
|
Jan 30
|
Regeneron to acquire 2seventy’s cell therapy pipeline
|
|
Jan 29
|
5 U.S. Corporate Giants to Buy on Solid Economic Data
|
|
Jan 29
|
Will New Drugs Drive Pfizer (PFE) Sales in Q4 Earnings?
|
|
Jan 27
|
3 Magnificent Stocks to Buy and Hold Forever
|
|
Jan 26
|
Earnings Preview: Regeneron (REGN) Q4 Earnings Expected to Decline
|
|
Jan 26
|
Regeneron Pharmaceuticals Inc Director Joseph Goldstein Sells 2,707 Shares
|
|
Jan 25
|
UPDATE 3-US FDA approves Dupixent to treat younger kids with esophageal condition
|
|
Jan 25
|
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
|
|
Jan 25
|
SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why
|
|
Jan 24
|
Gene therapy restores hearing in five of six deaf children in trial
|
|
Jan 24
|
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
|
|
Jan 16
|
Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
|
|
Jan 15
|
Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use
|
|
Jan 13
|
Investing in Regeneron Pharmaceuticals (NASDAQ:REGN) five years ago would have delivered you a 123% gain
|
|
Jan 12
|
Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again
|
|
Jan 12
|
Regeneron (REGN) Is Up 3.97% in One Week: What You Should Know
|
|
Jan 11
|
Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results
|
|
Jan 10
|
Corrections
|